Screener
Axsome Therapeutics AXSM Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Proceeds from issuance of common stock upon exercise of options | 9,981 | 17,035 |
| Payment of contingent consideration | (3,262) | (2,285) |
| Payments of tax withholdings on stock awards | (9,301) | (4,336) |
| Net cash provided by financing activities | 2,994 | 29,270 |
| Net decrease in cash | (17,827) | (14,443) |
| Cash at beginning of period | 322,933 | 315,353 |
| Cash at end of period | $305,106 | $300,910 |
| Supplemental disclosures of cash flow information: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's financing cash flow?
- Axsome Therapeutics (AXSM) reported financing cash flow of $2.99M in Q1 2026.
- How has Axsome Therapeutics's financing cash flow changed year-over-year?
- Axsome Therapeutics's financing cash flow decreased by 89.8% year-over-year, from $29.27M to $2.99M.
- What is the long-term trend for Axsome Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Axsome Therapeutics's financing cash flow has grown at a 73.8% compound annual growth rate (CAGR), from $11.13M to $101.47M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Axsome Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude